IL213341A0 - Dipeptide linked medicinal agents - Google Patents
Dipeptide linked medicinal agentsInfo
- Publication number
- IL213341A0 IL213341A0 IL213341A IL21334111A IL213341A0 IL 213341 A0 IL213341 A0 IL 213341A0 IL 213341 A IL213341 A IL 213341A IL 21334111 A IL21334111 A IL 21334111A IL 213341 A0 IL213341 A0 IL 213341A0
- Authority
- IL
- Israel
- Prior art keywords
- medicinal agents
- dipeptide linked
- dipeptide
- linked medicinal
- agents
- Prior art date
Links
- 108010016626 Dipeptides Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13922708P | 2008-12-19 | 2008-12-19 | |
| PCT/US2009/068711 WO2010080605A1 (en) | 2008-12-19 | 2009-12-18 | Dipeptide linked medicinal agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL213341A0 true IL213341A0 (en) | 2011-07-31 |
Family
ID=42316744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL213341A IL213341A0 (en) | 2008-12-19 | 2011-06-02 | Dipeptide linked medicinal agents |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20110237493A1 (enExample) |
| EP (1) | EP2376098A4 (enExample) |
| JP (2) | JP2012512898A (enExample) |
| KR (1) | KR20110114568A (enExample) |
| CN (1) | CN102300580A (enExample) |
| AU (1) | AU2009335711A1 (enExample) |
| CA (1) | CA2747195A1 (enExample) |
| IL (1) | IL213341A0 (enExample) |
| MX (1) | MX2011006527A (enExample) |
| PE (1) | PE20120331A1 (enExample) |
| RU (1) | RU2578591C2 (enExample) |
| SG (1) | SG172290A1 (enExample) |
| WO (1) | WO2010080605A1 (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2572952T3 (es) | 2005-11-07 | 2016-06-03 | Indiana University Research And Technology Corporation | Análogos de glucagón que muestran solubilidad y estabilidad fisiológicas |
| CA2674354A1 (en) | 2007-01-05 | 2008-07-17 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility in physiological ph buffers |
| KR20090119876A (ko) | 2007-02-15 | 2009-11-20 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 글루카곤/ｇｌｐ-1 수용체 공동-항진물질 |
| JP5669582B2 (ja) | 2007-10-30 | 2015-02-12 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | グルカゴンアンタゴニスト |
| AU2008318876B2 (en) | 2007-10-30 | 2014-05-15 | Indiana University Research And Technology Corporation | Compounds exhibiting glucagon antagonist and GLP-1 agonist activity |
| JP2011511778A (ja) | 2008-01-30 | 2011-04-14 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション | エステルに基づいたペプチドプロドラッグ |
| MX2010012695A (es) | 2008-06-17 | 2011-03-15 | Univ Indiana Res & Tech Corp | Analogos de glucagon que exhiben solubilidad y estabilidad aumentadas en soluciones reguladoras de ph fisiologico. |
| AU2009274425B2 (en) | 2008-06-17 | 2014-05-15 | Indiana University Research And Technology Corporation | GIP-based mixed agonists for treatment of metabolic disorders and obesity |
| WO2009155258A2 (en) | 2008-06-17 | 2009-12-23 | Indiana University Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
| EP2376520B1 (en) | 2008-12-19 | 2014-02-12 | Indiana University Research&Technology Corporation | Insulin analogs |
| EP2376521B1 (en) | 2008-12-19 | 2016-04-13 | Indiana University Research and Technology Corporation | Amide-based insulin prodrugs |
| MX2011006524A (es) | 2008-12-19 | 2011-08-17 | Univ Indiana Res & Tech Corp | Profarmacos de peptido de la superfamilia de glucagon basado en amida. |
| CN102459325B (zh) | 2009-06-16 | 2015-03-25 | 印第安纳大学科技研究有限公司 | 胃抑胜肽受体活化的胰高血糖素化合物 |
| WO2011075393A2 (en) | 2009-12-18 | 2011-06-23 | Indiana University Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
| KR20120123443A (ko) | 2010-01-27 | 2012-11-08 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 대사 장애 및 비만 치료용 글루카곤 길항제-ｇｉｐ 항진제 콘쥬게이트 |
| CA2797095A1 (en) | 2010-05-13 | 2011-11-17 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhibiting nuclear hormone receptor activity |
| CA2797089A1 (en) | 2010-05-13 | 2011-11-17 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhibiting g protein-coupled receptor activity |
| US8940860B2 (en) | 2010-06-16 | 2015-01-27 | Indiana University Research And Technology Corporation | Single-chain insulin agonists exhibiting high activity at the insulin receptor |
| CA2796879A1 (en) * | 2010-06-24 | 2011-12-29 | Indiana University Research And Technology Corporation | Dipeptide linked medicinal agents |
| JP5912112B2 (ja) | 2010-06-24 | 2016-04-27 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | アミド系インスリンプロドラッグ |
| CA2796894A1 (en) | 2010-06-24 | 2011-12-29 | Indiana University Research And Technology Corporation | Amide based glucagon superfamily peptide prodrugs |
| AU2011349331A1 (en) | 2010-12-22 | 2013-07-11 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting GIP receptor activity |
| RU2014101697A (ru) | 2011-06-22 | 2015-07-27 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Коагонисты рецепторов глюкагона/glp-1 |
| JP6179864B2 (ja) | 2011-06-22 | 2017-08-16 | インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション | グルカゴン／ｇｌｐ−１レセプタコ−アゴニスト |
| BR112014007124A2 (pt) * | 2011-11-17 | 2017-06-13 | Univ Indiana Res & Tech Corp | superfamília de peptídeos gluxagon que exibem atividade no receptor glicocorticóide |
| JP6392123B2 (ja) | 2011-12-20 | 2018-09-19 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | 糖尿病治療のためのｃｔｐ系インスリンアナローグ |
| CN103172726B (zh) * | 2011-12-22 | 2017-06-13 | 杭州淳泰科技有限公司 | 胰泌素类似物及其制备方法和用途 |
| EP2820038B1 (en) | 2012-03-01 | 2020-06-17 | Novo Nordisk A/S | Glp-1 prodrugs |
| RU2015101697A (ru) | 2012-06-21 | 2016-08-10 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Аналоги глюкагона, обладающие активностью рецептора gip |
| EP2900255B1 (en) | 2012-09-26 | 2019-01-30 | Indiana University Research and Technology Corporation | Insulin analog dimers |
| KR20150131213A (ko) | 2013-03-14 | 2015-11-24 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 인슐린-인크레틴 접합체들 |
| WO2015081891A1 (en) | 2013-12-06 | 2015-06-11 | Baikang (Suzhou) Co., Ltd | Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs |
| WO2016049190A1 (en) | 2014-09-24 | 2016-03-31 | Indiana University Research And Technology Corporation | Incretin-insulin conjugates |
| ES2947409T3 (es) | 2014-09-24 | 2023-08-08 | Univ Indiana Res & Tech Corp | Profármacos de insulina a base de amida lipídica |
| SI3464336T1 (sl) | 2016-06-01 | 2022-06-30 | Athira Pharma, Inc. | Spojine |
| US20230285578A1 (en) * | 2020-05-26 | 2023-09-14 | Indiana University Research And Technology Corporation | Pth analogs for the treatment of hypoparathyroidism |
| US20220177538A1 (en) | 2020-07-22 | 2022-06-09 | Novo Nordisk A/S | Co-agonists at glp-1 and gip receptors suitable for oral delivery |
| US20250268986A1 (en) | 2020-11-06 | 2025-08-28 | Novo Nordisk A/S | Glp-1 prodrugs and uses thereof |
| WO2023012263A1 (en) | 2021-08-04 | 2023-02-09 | Novo Nordisk A/S | Solid oral peptide formulations |
| TW202330584A (zh) | 2022-01-20 | 2023-08-01 | 丹麥商諾佛 儂迪克股份有限公司 | 前藥及其用途 |
| WO2023217744A1 (en) | 2022-05-10 | 2023-11-16 | Novo Nordisk A/S | Prodrugs of glp-1 polypeptide and uses thereof |
| TW202421645A (zh) | 2022-11-25 | 2024-06-01 | 丹麥商諾佛 儂迪克股份有限公司 | 如ｇｌｐ—１之肽治療劑的口服投與 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3740385A (en) * | 1970-05-07 | 1973-06-19 | M Ondetti | N-terminal derivatives of secretin |
| DK119785D0 (da) * | 1985-03-15 | 1985-03-15 | Nordisk Gentofte | Insulinpraeparat |
| US4741897A (en) * | 1986-07-08 | 1988-05-03 | Baxter Travenol | Thyroxine analogs and reagents for thyroid hormone assays |
| US5545618A (en) * | 1990-01-24 | 1996-08-13 | Buckley; Douglas I. | GLP-1 analogs useful for diabetes treatment |
| DE19828113A1 (de) * | 1998-06-24 | 2000-01-05 | Probiodrug Ges Fuer Arzneim | Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV |
| US20030236190A1 (en) * | 1998-09-02 | 2003-12-25 | Renuka Pillutla | Isulin and IGF-1 receptor agonists and antagonists |
| DE60012721T4 (de) * | 1999-03-29 | 2010-09-09 | Uutech Ltd., Coleraine | Analoge des magensaft inhibierenden peptides und ihre verwendung für die behandlung von diabetes |
| AUPQ661800A0 (en) * | 2000-03-31 | 2000-05-04 | Metabolic Pharmaceuticals Limited | Insulin-potentiating compounds |
| AU2001284697A1 (en) * | 2000-08-04 | 2002-02-18 | Dmi Biosciences, Inc. | Method of synthesizing diketopiperazines |
| AU2001296962A1 (en) * | 2000-09-29 | 2002-04-08 | Schering Corporation | Pegylated interleukin-10 |
| EP1243276A1 (en) * | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Elongated and multiple spacers containing activatible prodrugs |
| IL158418A0 (en) * | 2001-04-19 | 2004-05-12 | Scripps Research Inst | In vivo incorporation of unnatural amino acids |
| US7238663B2 (en) * | 2001-08-28 | 2007-07-03 | Eli Lilly And Company | Pre-mixes of GLP-1 and basal insulin |
| US7238656B2 (en) * | 2001-08-29 | 2007-07-03 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Protective factors against inflammation, burns and noxious stimuli |
| IL161848A0 (en) * | 2001-12-20 | 2005-11-20 | Lilly Co Eli | Insulin moldecule having protracted time action |
| FR2842209B1 (fr) * | 2002-07-09 | 2007-11-23 | Nouvelle protease aspartique dite saspase et son utilisation dans le domaine cosmetique et therapeutique | |
| JP2006520818A (ja) * | 2003-03-19 | 2006-09-14 | イーライ リリー アンド カンパニー | ポリエチレングリコール結合ｇｌｐ−１化合物 |
| AU2004228793B2 (en) * | 2003-04-08 | 2009-10-08 | Yeda Research And Development Co. Ltd. | Reversible pegylated drugs |
| GB0310593D0 (en) * | 2003-05-08 | 2003-06-11 | Leuven K U Res & Dev | Peptidic prodrugs |
| EP1670515A2 (en) * | 2003-09-19 | 2006-06-21 | Novo Nordisk A/S | Albumin-binding derivatives of therapeutic peptides |
| WO2005035003A2 (en) * | 2003-09-22 | 2005-04-21 | Dihedron Corporation | Compositions and methods for increasing drug efficiency |
| US8263545B2 (en) * | 2005-02-11 | 2012-09-11 | Amylin Pharmaceuticals, Inc. | GIP analog and hybrid polypeptides with selectable properties |
| CA2621847A1 (en) * | 2005-09-08 | 2007-03-15 | Shire Llc | Prodrugs of t3 and t4 with enhanced bioavailability |
| CN101432025B (zh) * | 2006-03-21 | 2012-04-04 | 安米林药品公司 | 肽-肽酶抑制剂结合物及其使用方法 |
| DK2615108T3 (en) * | 2006-09-08 | 2017-01-30 | Ambrx Inc | Modified human plasma polypeptide or fc scaffolds and their applications |
| DE102006052755A1 (de) * | 2006-11-08 | 2008-05-15 | N-Zyme Biotec Gmbh | Michaelsysteme als Transglutaminaseinhibitoren |
| KR20090119876A (ko) * | 2007-02-15 | 2009-11-20 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 글루카곤/ｇｌｐ-1 수용체 공동-항진물질 |
| JP2011511778A (ja) * | 2008-01-30 | 2011-04-14 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション | エステルに基づいたペプチドプロドラッグ |
| MX2011006524A (es) * | 2008-12-19 | 2011-08-17 | Univ Indiana Res & Tech Corp | Profarmacos de peptido de la superfamilia de glucagon basado en amida. |
-
2009
- 2009-12-18 CN CN2009801518123A patent/CN102300580A/zh active Pending
- 2009-12-18 JP JP2011542481A patent/JP2012512898A/ja not_active Withdrawn
- 2009-12-18 MX MX2011006527A patent/MX2011006527A/es active IP Right Grant
- 2009-12-18 PE PE2011001237A patent/PE20120331A1/es not_active Application Discontinuation
- 2009-12-18 SG SG2011045275A patent/SG172290A1/en unknown
- 2009-12-18 US US13/130,963 patent/US20110237493A1/en not_active Abandoned
- 2009-12-18 EP EP09837981.1A patent/EP2376098A4/en not_active Withdrawn
- 2009-12-18 CA CA2747195A patent/CA2747195A1/en not_active Abandoned
- 2009-12-18 WO PCT/US2009/068711 patent/WO2010080605A1/en not_active Ceased
- 2009-12-18 KR KR1020117016192A patent/KR20110114568A/ko not_active Ceased
- 2009-12-18 RU RU2011129764/04A patent/RU2578591C2/ru not_active IP Right Cessation
- 2009-12-18 AU AU2009335711A patent/AU2009335711A1/en not_active Abandoned
-
2011
- 2011-06-02 IL IL213341A patent/IL213341A0/en unknown
-
2015
- 2015-09-14 JP JP2015181062A patent/JP2016028082A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20110237493A1 (en) | 2011-09-29 |
| MX2011006527A (es) | 2011-08-17 |
| KR20110114568A (ko) | 2011-10-19 |
| JP2016028082A (ja) | 2016-02-25 |
| AU2009335711A1 (en) | 2010-07-15 |
| CA2747195A1 (en) | 2010-07-15 |
| SG172290A1 (en) | 2011-07-28 |
| JP2012512898A (ja) | 2012-06-07 |
| WO2010080605A1 (en) | 2010-07-15 |
| PE20120331A1 (es) | 2012-04-14 |
| RU2011129764A (ru) | 2013-01-27 |
| RU2578591C2 (ru) | 2016-03-27 |
| EP2376098A4 (en) | 2014-06-11 |
| EP2376098A1 (en) | 2011-10-19 |
| CN102300580A (zh) | 2011-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL213341A0 (en) | Dipeptide linked medicinal agents | |
| GB0811304D0 (en) | Therapeutic agents | |
| IL237391A0 (en) | Pharmaceutical combination | |
| GB0811643D0 (en) | New therapeutic agents | |
| GB0819593D0 (en) | Therapeutic agents | |
| ZA200906525B (en) | Therapeutic agents | |
| GB0801081D0 (en) | Therapeutic agents | |
| GB0821693D0 (en) | Therapeutic agents | |
| GB0723747D0 (en) | Therapeutic agents | |
| GB0801080D0 (en) | Therapeutic agents | |
| GB0812309D0 (en) | Therapeutic agents | |
| GB0805818D0 (en) | Therapeutic agents | |
| IL208953A0 (en) | Pharmaceutical combination | |
| GB0803054D0 (en) | Medicament | |
| PT2424870E (pt) | Agentes terapêuticos 713 | |
| EP2254901A4 (en) | THERAPEUTIC PEPTIDES | |
| GB0717450D0 (en) | Medicament | |
| EP2454276A4 (en) | THERAPEUTIC AGENTS | |
| GB0723748D0 (en) | Therapeutic agents | |
| HU0800414D0 (en) | Pharmaceutical combination | |
| GB0811715D0 (en) | Therapeutic agents | |
| GB0815177D0 (en) | Therapeutic agents | |
| GB0801082D0 (en) | Therapeutic agents | |
| GB0820275D0 (en) | Therapeutic agents | |
| GB0812563D0 (en) | Therapeutic agents |